Compare
NeuroPace Inc vs Anika Therapeutics, Inc. vs Orasure Technologies Inc vs Delcath Systems, Inc.
| Latest fiscal year | NeuroPace Inc NPCE | Anika Therapeutics, Inc. ANIK | Orasure Technologies Inc OSUR | Delcath Systems, Inc. DCTH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $99.99M | $112.82M | $115.02M | $85.23M |
| Revenue growth (YoY) | +25.1% | -5.9% | -38.1% | +129.1% |
| Gross margin | 77.2% | 56.6% | 41.9% | 86.2% |
| Operating margin | -16.3% | -9.8% | -62.6% | 0.8% |
| Net margin | -21.5% | -9.6% | -59.8% | 3.2% |
| Net income | -$21.46M | -$10.88M | -$68.73M | $2.70M |
| EPS (Diluted) | -$0.66 | -$0.76 | -$0.94 | $0.07 |
| Operating cash flow | -$11.01M | $11.19M | -$49.02M | $22.52M |
| Free cash flow | -$11.34M | $4.36M | -$53.22M | $20.97M |
| Cash & equivalents | $21.69M | $57.48M | $199.28M | $43.45M |
| Total assets | $105.56M | $190.27M | $403.17M | $123.63M |
| Total liabilities | $86.53M | n/a | $62.34M | $12.41M |
| Shareholders' equity | $19.03M | $143.47M | $340.83M | $111.22M |
| Return on year-end equity | -112.8% | -7.6% | -20.2% | 2.4% |
| Shares outstanding | 33.57M | 13.89M | 70.39M | 34.69M |
Revenue, most recent five fiscal years
| Fiscal year | NeuroPace Inc | Anika Therapeutics, Inc. | Orasure Technologies Inc | Delcath Systems, Inc. |
|---|---|---|---|---|
| Latest | $99.99M Ended 2025-12-31 | $112.82M Ended 2025-12-31 | $115.02M Ended 2025-12-31 | $85.23M Ended 2025-12-31 |
| 1 year earlier | $79.91M Ended 2024-12-31 | $119.91M Ended 2024-12-31 | $185.83M Ended 2024-12-31 | $37.20M Ended 2024-12-31 |
| 2 years earlier | $65.42M Ended 2023-12-31 | $120.79M Ended 2023-12-31 | $405.47M Ended 2023-12-31 | $2.06M Ended 2023-12-31 |
| 3 years earlier | $45.52M Ended 2022-12-31 | $113.83M Ended 2022-12-31 | $387.48M Ended 2022-12-31 | $2.72M Ended 2022-12-31 |
| 4 years earlier | $45.18M Ended 2021-12-31 | $147.79M Ended 2021-12-31 | $233.67M Ended 2021-12-31 | $3.56M Ended 2021-12-31 |